<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02616445</url>
  </required_header>
  <id_info>
    <org_study_id>ACW0001</org_study_id>
    <nct_id>NCT02616445</nct_id>
  </id_info>
  <brief_title>Phase I MAD, Fed-Fasted, CSF Study of UE2343 in Healthy Subjects</brief_title>
  <official_title>A Phase I Double-Blind, Randomised, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of UE2343 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actinogen Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novotech (Australia) Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Linear Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Actinogen Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the drug UE2343, a potential treatment for
      Alzheimer's Disease (AD), is effective by assessing safety, tolerability, pharmacokinetics
      and pharmacodynamics in a Multiple Ascending Dose Study. Protocol amendments to the study
      will examine any food effect and determine if the drug penetrates the Blood-Brain Barrier.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 of this study is a double-blind, randomised, placebo-controlled, multiple ascending
      dose study to assess the safety, tolerability, PK and PD in healthy participants dosed twice
      daily at levels of 10, 20 and 35mg for 10 days.This part of the study will recruit 3 groups
      of 8 participants each.

      Part 2 is a cross-over study to assess the effects of food on the PK of UE2343 in healthy
      participants dosed with two single doses at a level decided from Part 1. This part of the
      study will recruit a total of 12 participants.

      Part 3 seeks to determine the PK of the UE2343 in CSF of healthy participants dosed twice
      daily for 4 days with a dose level determined from Part 1 and 2. This part of the study will
      recruit 4 participants.

      Strategies to ensure adherence to the study include the requirement that participants remain
      at the clinical research facility for the duration of their participation in the study; drug
      accountability checks (i.e. reconciliation of used and unused capsules) by an independent
      clinical research associate; and administration of the capsules to the participant by a
      member of the study site team.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess Safety and Tolerability of UE2343 over 17 days including AEs, 12-lead ECGs, vital signs, Nerve conduction velocity, Labs.</measure>
    <time_frame>Up to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the Pharmacokinetic (PK) Plasma Parameter Maximum Plasma Concentration (Cmax) of UE2343 after a single dose</measure>
    <time_frame>Day 1 and Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the Pharmacokinetic (PK) Plasma Parameter Time to Cmax (Tmax) of UE2343 after a single dose</measure>
    <time_frame>Day 1 and Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the Pharmacokinetic (PK) Plasma Parameter Area Under the Curve (AUC) of UE2343 after a single dose</measure>
    <time_frame>Day 1 and Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the Pharmacokinetic (PK) Plasma Parameter Terminal Elimination Half Life (t½) of UE2343 after a single dose</measure>
    <time_frame>Day 1 and Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess PK Parameter Maximum Plasma Concentration (Cmax) of UE2343 in CSF</measure>
    <time_frame>Day 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess Pharmacokinetics (PK) Plasma parameter Maximum Plasma Concentration (Cmax) from time of dosing to 12 hours</measure>
    <time_frame>Day 1 and Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Pharmacokinetics (PK) Plasma parameter Time to Cmax (Tmax) from time of dosing to 12 hours</measure>
    <time_frame>Day 1 and Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Pharmacokinetics (PK) Plasma parameter Area Under the Curve (AUC) from time of dosing to 12 hours</measure>
    <time_frame>Day 1 and Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Pharmacokinetics (PK) Plasma parameter Terminal Elimination Half Life (t½) from time of dosing to 12 hours</measure>
    <time_frame>Day 1 and Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Pharmacokinetics (PK) Urine parameters (Amount of drug excreted in urine (Ae) and Ae as a % of dose) from time of dosing to 24 hours</measure>
    <time_frame>Day 1 and Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess PK Parameter Maximum Plasma Concentration (Cmax) of UE2343 in CSF compared to the Cmax value obtained in plasma</measure>
    <time_frame>Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Pharmacodynamics (PD) Blood parameter Adrenocorticotropic hormone (ACTH) from baseline to end of study</measure>
    <time_frame>Days 1, 10, 11, 12, 13 and 17.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Pharmacodynamics (PD) Blood parameter Serum Cortisol from baseline to end of study</measure>
    <time_frame>Days 1, 10, 11, 12, 13 and 17.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Pharmacodynamics (PD) Blood parameter for Adrenal Androgens from baseline to end of study</measure>
    <time_frame>Days 1, 10, 11, 12, 13 and 17.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Pharmacodynamics (PD) Urine parameter Urinary Free Cortisol (UFF) from baseline to end of study</measure>
    <time_frame>Days 1, 10, 11 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Pharmacodynamics (PD) Urine parameter Urinary Free Cortisone (UFE) from baseline to end of study</measure>
    <time_frame>Days 1, 10, 11 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Pharmacodynamics (PD) Urine parameter 5α-tetrahydrocortisol (5αTHF) from baseline to end of study</measure>
    <time_frame>Days 1, 10, 11 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Pharmacodynamics (PD) Urine parameter 5β-tetrahydrocortisol (5βTHF) from baseline to end of study</measure>
    <time_frame>Days 1, 10, 11 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Pharmacodynamics (PD) Urine parameter tetrahydrocortisone (THE) from baseline to end of study</measure>
    <time_frame>Days 1, 10, 11 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>MAD Study</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fed-Fasted</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UE2343</intervention_name>
    <description>UE2343
10mg, 20, 35mg
twice daily for 9 days</description>
    <arm_group_label>MAD Study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10mg, 20, 35mg
twice daily for 9 days</description>
    <arm_group_label>MAD Study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Cross-over study
single dose administered twice (on day 1 and day 8)
study duration 17 days</description>
    <arm_group_label>Fed-Fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UE2343</intervention_name>
    <description>Cross-over study
UE2343
single dose administered twice (on day 1 and day 8)
study duration 17 days</description>
    <arm_group_label>Fed-Fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UE2343</intervention_name>
    <description>UE2343
twice daily for 3 days
single dose on day 4</description>
    <arm_group_label>CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to use specified contraception

          -  BMI within specified range

          -  No clinically significant abnormalities in the results of laboratory evaluations at
             Screening and Day -1.

        Exclusion Criteria:

          -  Abnormal medical history, including history of dementia

          -  No significant allergic reactions

          -  No prior drug or alcohol abuse

          -  Use of regular prescribed medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Ruffles</last_name>
    <role>Study Chair</role>
    <affiliation>Actinogen Medical</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janakan Krishnarajah</last_name>
    <role>Principal Investigator</role>
    <affiliation>Linear Clinical Research Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <results_reference>
    <citation>Webster SP, McBride A, Binnie M, Sooy K, Seckl JR, Andrew R, Pallin TD, Hunt HJ, Perrior TR, Ruffles VS, Ketelbey JW, Boyd A, Walker BR. Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™). Br J Pharmacol. 2017 Mar;174(5):396-408. doi: 10.1111/bph.13699. Epub 2017 Jan 25.</citation>
    <PMID>28012176</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2015</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Xanamem</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

